HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and export services, with a "1+2+3+4=1" service system and supply channels for original PCL pellets from multiple well-known brands.
As a tech R&D-oriented foreign trade enterprise, HiSiaddi has repeatedly put forward PCL pellet formula optimization schemes and application improvement suggestions by leveraging technology transformation cooperation with manufacturers and precise market demand insight. Below is a consultation case of HiSiaddi on PCL pellet formula optimization.
For more formula optimization consultation services, please contact HiSiaddi customer service.
HiSiaddi completely resolves implementation challenges from formula improvement, production process adjustment to end-product processing across all dimensions
The cooperating customer is BioImplants GmbH, headquartered in the biomedical industrial park of Würzburg, Germany. It is a medium-to-high-end specialized manufacturing enterprise deeply engaged in orthopedic implant consumables, long-acting sustained-release drug microspheres and medical aesthetic soft tissue filling materials in Germany. Its products are supplied to federal public hospitals across Germany and multiple listed pharmaceutical enterprises in Europe, and it consistently complies with EU MDR medical device specifications, ISO 10993 biosafety standards and the 6th edition USP medical raw material standards. It maintains an annual stable medical-grade PCL procurement volume of 220 tons and has long sourced original imported PCL raw materials from Perstorp (Sweden) and Evonik (Germany), relying on imported raw materials to stably operate two core production lines: FDM 3D printing of orthopedic stents and emulsion-based drug microsphere mass production.
Affected by maintenance shutdowns of local European chemical facilities, surging overseas raw material prices and extended delivery cycles of over 100 days, the customer launched a domestic PCL substitution procurement project. After preliminary sample screening, raw materials from two leading domestic PCL manufacturers were selected, with an initial purchase of 52 tons of domestic medical-grade PCL pellets. After arrival and warehousing, mass production failures occurred continuously: broken extrusion filaments during 3D printing of orthopedic stents, warpage and cracking of finished products, particle agglomeration of sustained-release drug microspheres, excessive particle size span and drastically reduced drug encapsulation efficiency. The pass rate of the two core production lines plummeted from 96% using original imported raw materials to less than 53%, forcing intermittent production line shutdowns. The customer faced risks including delayed delivery compensation for downstream medical device orders and loss risks caused by nearly 40 tons of overstocked raw materials.
The customer contacted technical staff from the two raw material suppliers successively, yet manufacturers only made minor parameter adjustments based on their own product formulas, which could only slightly alleviate defects without complete elimination. Focused on mass production of standard grades, manufacturers refused to invest costs in targeted optimization of formulas and polymerization processes. Recommended by the German Chemical Materials Association, the customer fully entrusted Shanghai HiSiaddi Technology (referred to as HiSiaddi) as a third-party technical foreign trade service provider. Relying on HiSiaddi’s team of polymer engineers and medical raw material R&D personnel, we thoroughly analyzed raw material physical and chemical defects, formula shortcomings and end-product processing adaptation issues, and implemented rectifications in three phases: raw material formula optimization, upstream factory production technical transformation and adjustment of customer end-line processing parameters, completely resolving mass production failures and realizing stable domestic PCL substitution.
Basic product information: Medical-grade PCL pellets, HS code 3907999000, export packaging in 25kg sterile cardboard drums lined with aluminum foil, divided into two grades: high-viscosity raw material for orthopedic stents and medium-viscosity raw material for drug sustained-release microspheres.
The customer’s original imported PCL adopts precise end-capping polymerization technology with narrow molecular weight distribution and low small-molecule oligomer content. Restricted by polymerization formulas, catalyst ratios and devolatilization processes, domestic raw materials feature two key drawbacks:
1. Excessively wide molecular weight distribution and over-limit PDI index The measured PDI of orthopedic dedicated grade reached 1.78 (vs. ≤1.35 for imported materials). The drastic difference in molecular chain length led to severe melt viscosity fluctuation in molten state, causing uneven extrusion thickness during 3D printing, frequent nozzle clogging and filament breakage, and uneven internal stress after cooling and molding, resulting in large-scale warpage and deformation of stents after 24 hours of ambient storage.
2. High residual small-molecule oligomers and catalysts Domestic raw materials lack in-depth vacuum devolatilization, with caprolactone monomer residue at 280ppm and tin catalyst residue at 52ppm. Small-molecule impurities dissolve in the organic phase during microsphere preparation via emulsification, disrupting the stability of oil-water two-phase interfaces and causing adhesion and agglomeration during microsphere curing. The D50 particle size span expanded from ±5μm for imported materials to ±32μm, and drugs were wrapped by precipitates of free small molecules, reducing encapsulation efficiency from 87% to 52%, failing to meet the mandatory EU pharmacopoeia indicators for sustained-release preparations.
3. Uncontrollable internal molecular crystallinity Without trace medical modifier additives in the formula, the crystallinity fluctuation range of raw materials stood at 12%~19%. Processing performance varied between raw material bags within the same batch, requiring repeated equipment parameter debugging after each barrel change and preventing continuous large-scale production.
Domestic manufacturers adopt conventional air-cooled cutting processes, resulting in tiny hollow and micropore defects inside pellets with high pellet voidage. Water vapor trapped inside micropores during raw material drying instantly vaporizes upon high-temperature melting processing, causing internal pores in stents and hollow scrapped microspheres. Meanwhile, pellet size fluctuated by ±0.5mm, leading to uneven feeding speed and further aggravating extrusion instability.
All customer equipment was customized with temperature control, screw speed and extrusion pressure parameters matching imported European PCL. The customer continued to use original processing parameters without targeted adjustment of temperature curves, cooling wind speed and stirring rotation speed to adapt to the distinct melting temperature, melt fluidity and crystallization rate of domestic raw materials. Superimposed with inherent raw material performance defects, multiple factors amplified defect rates, serving as the direct inducement for concentrated production failures.
Limited to minor processing suggestions, both raw material manufacturers refused to modify existing polymerization formulas and production lines, putting the customer in a dilemma of unprocessable raw materials and high losses from product returns.
Combining test data of imported raw materials and the customer’s end-product application standards, two polymer engineers from HiSiaddi optimized the domestic PCL polymerization system item by item:
1. Adjust end-capping agent ratio to narrow molecular weight distribution We guided manufacturers to replace metering feeding systems, precisely control the molar ratio of hexadecanol terminator and tin octoate catalyst, and adopt segmented gradient temperature rise ring-opening polymerization with three temperature stages of 112℃, 124℃ and 133℃ to strictly control polymerization rates. After optimization, the PDI of orthopedic grade dropped to 1.32 and microsphere grade to 1.29, both superior to customer usage standards, with melt viscosity fluctuation controlled within ±4% to fundamentally resolve unstable extrusion issues.
2. Add three-stage negative-pressure high-temperature devolatilization to strictly control impurity residues Three-stage high-vacuum devolatilization was added post-polymerization with stepped negative pressure at 205℃, 220℃ and 235℃ to remove free monomers, oligomers and residual catalysts, combined with medical-grade supercritical extraction refinement. After rectification, monomer residue ≤130ppm and tin catalyst residue ≤18ppm, drastically reducing small-molecule impurities and resolving microsphere adhesion and insufficient drug encapsulation efficiency pain points.
3. Add trace pharmacopoeia-grade modifiers to stabilize crystallinity 0.35% food and medical-grade sebacic acid modifier was added at the late polymerization stage to uniformly regulate PCL crystallinity at a stable 14.5%±0.8%, ensuring consistent physical properties of raw materials within the same batch and eliminating repeated equipment debugging during material switching.
HiSiaddi guided manufacturers to renovate pelletizing production lines: replace conventional die heads with customized precision-aperture die heads for orthopedic and microsphere grades respectively, adopt low-temperature underwater circumferential cutting + fluidized bed low-temperature negative-pressure drying to strictly control pellet moisture content below 0.12%. Matching online graded screening equipment to remove hollow and irregular pellets, the dimensional error of finished pellets was controlled within ±0.15mm, eliminating processing defects caused by water vapor trapped inside hollow pellets.
Manufacturers first produced 300kg optimized samples and sent them to Germany for full laboratory physical and chemical testing.
HiSiaddi compiled German-English bilingual process operation manuals and remotely coordinated the customer’s R&D department to adjust equipment parameters on both production lines:
1. Orthopedic 3D printing production line Raw material drying temperature reduced from 60℃ to 52℃ with drying time extended to 6h; overall barrel temperature of extrusion cylinder lowered by 3~5℃ to reduce risks of high-temperature thermal degradation; printer head extrusion pressure reduced by 12% and filament speed increased by 5% to match melting characteristics of optimized PCL; cooling air duct wind speed adjusted to slow cooling rate and release internal stress, avoiding stent warpage and cracking.
2. Drug microsphere emulsification production line Adjust organic phase feeding temperature and water phase stirring rotation speed, reduce dispersed phase dropping rate by 18% to match the dissolution rate and interfacial tension of new raw materials, optimize solvent gradient volatilization temperature control for stable curing and molding to improve microsphere agglomeration issues.
1. Upgrade compliance documents Cooperating with third-party EU laboratories, HiSiaddi reissued complete SGS biocompatibility test reports and COA quality inspection sheets for optimized PCL, compiled German-English bilingual SDS in accordance with German CLP regulations, supplemented REACH-SVHC screening and SCIP database notification documents to meet customer medical device warehousing audit and incoming material audit requirements of downstream pharmaceutical enterprises.
2. Packaging and export control Optimize sterile vacuum packaging processes to isolate moisture risks during storage and transportation, standardize bilingual RoHS labels on outer packaging; complete pre-audit of domestic customs declaration and filing of German customs clearance documents in advance to guarantee smooth export of subsequent mass cargo.
Small-batch trial mass production with optimized samples completely eliminated broken filaments and warpage of 3D printed orthopedic stents, with the pass rate rebounding to 97.1%. The D50 fluctuation of sustained-release drug microspheres was controlled within ≤6μm, drug encapsulation efficiency increased to 86.3% without infinite adhesion and agglomeration, fully reaching the processing performance level of imported raw materials. The remaining 49 tons of raw materials in inventory were returned to the factory in two batches for formula modification treatment and successfully put into production after rectification, restoring full-load operation of the customer’s two production lines and avoiding order breach losses of approximately EUR 126,000. Cost accounting showed that the unit procurement price of optimized domestic PCL decreased by 27.5% compared with original imported raw materials, significantly reducing single-batch production costs.
In Q4 2025, BioImplants GmbH from Germany signed an annual PCL procurement framework agreement with HiSiaddi, locking in an annual procurement volume of 210 tons. HiSiaddi agreed to provide full-process technical services covering raw material formula iteration, regulation updates and process fine-tuning on an ongoing basis. Leveraging mature existing formulas, the customer simultaneously launched R&D of PCL dedicated to absorbable surgical sutures, entrusting HiSiaddi to coordinate upstream manufacturers for formula development and sample verification.
Relying on this benchmark case of PCL formula and processing technology troubleshooting, HiSiaddi leveraged the customer’s industry resources in Germany to successfully contact two medium-to-high-end biomaterial manufacturers in Austria and the Czech Republic, replicating the integrated technical foreign trade service model of "raw material formula optimization + process debugging + compliance support" and delivering multiple batches of samples and mass orders, forming core technical service competitiveness distinguishing HiSiaddi from traditional spot traders.
The core contradiction of this case lies in the fact that domestic PCL manufacturers are accustomed to standardized mass production and lack capacity for formula customization and process improvement targeting end-product processing scenarios of high-end European medical customers, resulting in objective performance gaps between domestic raw materials and imported grades. Coupled with the customer’s continued use of processing parameters for imported raw materials, mass production of defective products occurred in large quantities. Breaking away from the traditional foreign trade model focused solely on raw material sales, HiSiaddi takes material technology as the core starting point to systematically investigate failures and implement targeted optimization solutions across three dimensions: upstream polymerization formulas, factory pelletizing production and downstream end-product processing. We not only resolved the customer’s urgent production shutdown crisis but also realized stable domestic substitution of raw materials through technical empowerment. Against the backdrop of intensified fluctuations in global medical polymer raw material supply chains, relying on professional technology to resolve formula and production implementation challenges serves as the key path for chemical foreign trade to deeply cultivate high-end overseas customers and break free from low-price involution.
For more formula optimization consultation services, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
